|

CBA-1205 Part 3 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Chiome Bioscience Inc.1

Indications

  • Liver Disease1
  • Hepatocellular Carcinoma (HCC)1
  • Malignant Melanoma1
  • Solid Tumors1
  • Pediatric Cancer1

Other1 trial

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.